首页> 外国专利> METHODS FOR RISK ASSESSMENT, SURVIVAL PREDICTION AND TREATMENT OF HEART FAILURE AND OTHER CONDITIONS BASED ON ADRENERGIC RECEPTOR POLYMORPHISMS

METHODS FOR RISK ASSESSMENT, SURVIVAL PREDICTION AND TREATMENT OF HEART FAILURE AND OTHER CONDITIONS BASED ON ADRENERGIC RECEPTOR POLYMORPHISMS

机译:肾上腺素受体多态性的心力衰竭及其他情况的风险评估,生存预测和治疗方法

摘要

Methods and compositions for the detection, diagnosis, and prevention of cardiac conditions are provided. Polymorphisms of β1-adrenergic receptor are provided. The Gly389 β1-adrenergic receptor variants are not as responsive to treatment β blockers such as carvedilol, metoprolol or bisoprol. Thus, genotyping β1-adrenergic receptor polymorphisms is useful for predicting relative responsiveness to treatment with beta blockers. The Gly389 polymorphism also may be used, alone or in conjunction with other adrenergic receptor polymorphisms, to predict relative risk of developing cardiovascular diseases such as heart failure or to predict relative survival rate in patients with heart failure or other cardiovascular diseases. Also provided are transgenic mice and transgenic cells expressing the β1-adrenergic receptor polymorphisms, and their use in identifying therapeutic agents.
机译:提供了用于检测,诊断和预防心脏疾病的方法和组合物。提供了β1-肾上腺素能受体的多态性。 Gly389β1-肾上腺素能受体变体对治疗β受体阻滞剂的反应不佳,例如卡维地洛,美托洛尔或比索洛尔。因此,对β1-肾上腺素能受体多态性进行基因分型可用于预测对β受体阻滞剂治疗的相对反应性。 Gly389多态性还可以单独或与其他肾上腺素能受体多态性结合使用,以预测发生心血管疾病如心力衰竭的相对风险,或预测患有心力衰竭或其他心血管疾病的患者的相对存活率。还提供了表达β1-肾上腺素能受体多态性的转基因小鼠和转基因细胞,及其在鉴定治疗剂中的用途。

著录项

  • 公开/公告号EP1670954B1

    专利类型

  • 公开/公告日2010-11-24

    原文格式PDF

  • 申请/专利权人 UNIV CINCINNATI;

    申请/专利号EP20040816181

  • 申请日2004-09-13

  • 分类号C12Q1/68;

  • 国家 EP

  • 入库时间 2022-08-21 18:00:09

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号